Understanding how lung bacteria affect cancer treatment response
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
This study is looking at how the bacteria in your lungs might affect how well immunotherapy works for non-small cell lung cancer, and it aims to find patterns that could help doctors tailor treatments just for you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10879861 on NIH RePORTER |
What this research studies
This research investigates the role of lung microbiota in influencing the effectiveness of immunotherapy for non-small cell lung cancer (NSCLC). By analyzing the microbial signatures in the lower airways, the study aims to identify specific patterns that may predict how well patients respond to PD-1 blockade therapy. Patients will undergo longitudinal assessments, including sampling of airway, stool, and blood, to correlate these microbiota profiles with treatment outcomes. The goal is to enhance personalized treatment strategies based on individual microbiome characteristics.
Who could benefit from this research
Good fit: Ideal candidates are individuals diagnosed with non-small cell lung cancer who are considering or undergoing PD-1 blockade therapy.
Not a fit: Patients with other types of lung cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized immunotherapy treatments for lung cancer patients.
How similar studies have performed: Previous research has shown promising results in understanding the gut microbiome's impact on cancer treatment, but this specific focus on lung microbiota is relatively novel.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Segal, Leopoldo Nicolas — New York University School of Medicine
- Study coordinator: Segal, Leopoldo Nicolas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.